Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15834MR)

This product GTTS-WQ15834MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15834MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13963MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ522MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ575MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ1205MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ1297MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ5450MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ2319MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ9552MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW